Berenberg downgraded Huber+Suhner AG’s rating from “Buy” to “Hold”, arguing that the more than three‑fold rise in the share price over the past twelve months leaves little room for further upside. The brokerage simultaneously raised its price target to CHF250 from CHF200, reflecting confidence in the company’s emerging optical circuit switch (OCS) business and continued demand from aerospace and defence customers.

The stock closed at CHF259.50 on 15 June 2026 on the SIX Swiss Exchange, marking a decline of just over 4% and valuing the group at CHF4.79 billion. The 52‑week high and low were CHF287 and CHF85.40 respectively.

Berenberg projects the OCS unit to generate close to CHF400 million in sales by 2028, representing roughly 27% of total group revenue and 40% of group EBIT. The firm’s forecasts are anchored on an initial hyperscaler order that is expected to replace a spine‑leaf network topology, with additional sales from new customers beginning in 2028. The total potential contract value of the multi‑year agreement with the unnamed hyperscaler is estimated at approximately CHF650 million over three years, with Polatis sales under the contract forecast at CHF79 million in 2026, CHF211 million in 2027 and CHF362 million in 2028.

For the OCS unit, Berenberg assumes a 25% EBIT margin, positioned between the group’s current margin and the 40% margin guided by peer Lumentum Holdings. On the production side, the first third‑generation assembly line has arrived at the Pisary, Poland facility, and a second line is expected in August to support the first hyperscaler order. The company has shifted production for other customers to the UK, moved sub‑assembly work to external suppliers, and subcontracted work to its sister facility in Poland.

Valuation-wise, Berenberg notes that Huber+Suhner shares trade at 27 times forecast 2027 EV/EBIT, representing a 25% discount to Lumentum, its closest peer in the OCS market. The brokerage raised its 2027 sales estimate by 3.1% to CHF1.20 billion, its 2027 EBIT estimate by 9.8% to CHF169 million, and its 2027 EPS estimate by 14.2% to CHF7.60.

The note flags several risks: potential cuts or delays to defence budgets, supply‑chain disruptions affecting raw‑material and input costs, and competition from larger U.S. peers with more extensive research and development budgets.